What's Happening?
Hackensack Meridian Health has partnered with Israeli startup SpotitEarly to study an innovative cancer detection method that combines artificial intelligence with the scent detection capabilities of trained dogs. The collaboration aims to validate SpotitEarly's breath-based, at-home early detection test, which is set to launch in the U.S. next year. The study will focus initially on breast cancer detection, with plans to expand to other cancer types. The research will be conducted at the Hackensack Meridian John Theurer Cancer Center.
Why It's Important?
This partnership represents a significant advancement in cancer detection technology, potentially offering a non-invasive, accessible, and accurate method for early cancer screening. Early detection is crucial for improving cancer treatment outcomes and survival rates. The use of AI and canine scent detection could revolutionize the way cancers are diagnosed, making screening more widely available and less invasive. This could lead to earlier interventions and better patient prognoses.
What's Next?
The research collaboration will begin with the PINK Study, a multi-center trial focusing on breast cancer detection. If successful, the technology could be expanded to detect other types of cancer. SpotitEarly plans to seek FDA approval and commercialize the test in the U.S. The study's outcomes could influence future cancer screening guidelines and encourage further research into innovative detection methods.
